162 related articles for article (PubMed ID: 34758608)
1. Detection of
Baer C; Meggendorfer M; Haferlach C; Kern W; Haferlach T
Haematologica; 2022 Feb; 107(2):562-563. PubMed ID: 34758608
[No Abstract] [Full Text] [Related]
2. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
Sanchez R; Ayala R; Alonso RA; Martínez MP; Ribera J; García O; Sanchez-Pina J; Mercadal S; Montesinos P; Martino R; Barba P; González-Campos J; Barrios M; Lavilla E; Gil C; Bernal T; Escoda L; Abella E; Amigo ML; Moreno MJ; Bravo P; Guàrdia R; Hernández-Rivas JM; García-Guiñón A; Piernas S; Ribera JM; Martínez-López J
Ann Hematol; 2017 Jul; 96(7):1069-1075. PubMed ID: 28451802
[TBL] [Abstract][Full Text] [Related]
3. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
[No Abstract] [Full Text] [Related]
4. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
[TBL] [Abstract][Full Text] [Related]
5. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
Short NJ; Kantarjian H; Kanagal-Shamanna R; Sasaki K; Ravandi F; Cortes J; Konopleva M; Issa GC; Kornblau SM; Garcia-Manero G; Garris R; Higgins J; Pratt G; Williams LN; Valentine CC; Rivera VM; Pritchard J; Salk JJ; Radich J; Jabbour E
Blood Cancer J; 2020 May; 10(5):61. PubMed ID: 32457305
[TBL] [Abstract][Full Text] [Related]
6. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
8. [Mutations in the BCR-ABL1 gene in a peruvian patient with acute lymphoblastic leukemia resistant to therapy].
Ortiz CA; Alvarez YP; Dongo-Pflucker KL; Valdivia E; Mendoza Fernández J; Dávila S; Mora-Alférez P
Rev Fac Cien Med Univ Nac Cordoba; 2017; 74(2):162-166. PubMed ID: 28657534
[TBL] [Abstract][Full Text] [Related]
9. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
10. In Ph+BCR-ABL1
Baccarani M; Iacobucci I; Chiaretti S; Foà' R; Balasubramanian P; Paietta E; Foroni L; Jeromin S; Izzo B; Spinelli O; Varma N; Menif S; Terragna C; Seth T; Bidet A; Coriu D; Lunghi F; Mayer J; Scappini B; Langabeer S; Maier J; Burt E; Candoni A; Albano F; Luppi M; Zupan I; Lion T; Zadro R; di Raimondo F; Poopak B; Rege-Cambrin G; Annunziata M; Ayala A; Salinas-Viedma V; Ines Prado A; Milner B; Galimberti S; Janssen J; Polli V; Comba L; Borsellino B; Annibali O; Crugnola M; Passamonti F
Leukemia; 2020 Mar; 34(3):929-931. PubMed ID: 31595038
[No Abstract] [Full Text] [Related]
11. BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with
Takahashi T; Ichikawa S; Ichinohasama R; Harigae H
Leuk Lymphoma; 2020 May; 61(5):1265-1267. PubMed ID: 31876209
[No Abstract] [Full Text] [Related]
12. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.
Soverini S; Vitale A; Poerio A; Gnani A; Colarossi S; Iacobucci I; Cimino G; Elia L; Lonetti A; Vignetti M; Paolini S; Meloni G; di Maio V; Papayannidis C; Amabile M; Guarini A; Baccarani M; Martinelli G; Foà R
Haematologica; 2011 Apr; 96(4):552-7. PubMed ID: 21193419
[TBL] [Abstract][Full Text] [Related]
13. Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion.
De Braekeleer E; Douet-Guilbert N; Guardiola P; Rowe D; Mustjoki S; Zamecnikova A; Al Bahar S; Jaramillo G; Berthou C; Bown N; Porkka K; Ochoa C; De Braekeleer M
Leukemia; 2013 Jun; 27(6):1422-4. PubMed ID: 23168614
[No Abstract] [Full Text] [Related]
14. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
15.
Jain S; Abraham A
Arch Pathol Lab Med; 2020 Feb; 144(2):150-155. PubMed ID: 31644323
[TBL] [Abstract][Full Text] [Related]
16. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
Chiaretti S; Messina M; Foà R
Cancer; 2019 Jan; 125(2):194-204. PubMed ID: 30561755
[TBL] [Abstract][Full Text] [Related]
17. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
Płotka A; Lewandowski K
Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
[TBL] [Abstract][Full Text] [Related]
18. BCR/ABL1-positive acute lymphoblastic leukemia relapsing as BCR/ABL1-negative acute lymphoblastic leukemia.
Rizzotto L; Saccenti E; Sofritti O; Daghia G; Volta E; Caprini E; Lupini L; Tammiso E; Bardi A; Lista E; Ciccone M; Russo G; Negrini M; Cuneo A; Rigolin GM
Leuk Lymphoma; 2013 Sep; 54(9):2065-7. PubMed ID: 23323950
[No Abstract] [Full Text] [Related]
19. The e1a3 BCR-ABL1 fusion transcript in philadelphia chromosome-positive acute lymphoblastic leukemia.
Langabeer SE
Ann Lab Med; 2015 Sep; 35(5):540-1. PubMed ID: 26206693
[No Abstract] [Full Text] [Related]
20. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S; Martelli M; Bavaro L; De Benedittis C; Papayannidis C; Sartor C; Sorà F; Albano F; Galimberti S; Abruzzese E; Annunziata M; Russo S; Stulle M; Imovilli A; Bonifacio M; Maino E; Stagno F; Maria Basilico C; Borlenghi E; Fozza C; Mignone F; Minari R; Stella S; Baccarani M; Cavo M; Martinelli G
Br J Haematol; 2021 Apr; 193(2):271-279. PubMed ID: 33403687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
